ARTICLE | Product Development
Antidepression triad
March 19, 2007 7:00 AM UTC
Although sanofi-aventis Group has not hidden the fact it has moved three antidepressant and anxiolytic molecules into late-stage development, it has revealed few details. Now, the company is beginning to lift the veil, describing the compounds as first-in-class molecules with novel mechanisms that it believes could be complementary to marketed drugs.
Saredutant (SR 48968), a specific antagonist at neurokinin 2 (NK2) receptors, has a bolus of Phase III data due this year...